Mariathas Mark, Rawlins John, Curzen Nick
Coronary Research Group, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.
Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK.
Future Cardiol. 2017 Nov;13(6):551-566. doi: 10.2217/fca-2017-0056. Epub 2017 Oct 24.
Transcatheter aortic valve implantation (TAVI) was first used in clinical practice in 2002. Since 2002, there has been a rapid increase in TAVI activity in patients with symptomatic severe aortic stenosis. This has been supported by systematic randomized data comparing TAVI against the gold standard treatment for the last 50 years' surgical aortic valve replacement. TAVI is now currently a recommended therapeutic intervention in the treatment of severe aortic stenosis patients who are deemed either high risk or inoperable. The indications for TAVI continue to expand. Within this review we will focus on the current guidelines for TAVI, the evidence for it, the complications of TAVI, postprocedure care, the technology available to clinicians now and finally the future perspectives for TAVI.
经导管主动脉瓣植入术（TAVI）于2002年首次应用于临床实践。自2002年以来，有症状的重度主动脉瓣狭窄患者接受TAVI治疗的情况迅速增加。过去50年中，将TAVI与外科主动脉瓣置换这一金标准治疗方法进行比较的系统性随机数据支持了这一趋势。目前，TAVI是治疗被认为具有高风险或无法进行手术的重度主动脉瓣狭窄患者的推荐治疗干预措施。TAVI的适应证不断扩大。在本综述中，我们将重点关注TAVI的现行指南、其依据的证据、TAVI的并发症、术后护理、临床医生目前可采用的技术以及TAVI的未来前景。
